Aptahem CEO presents their lead candidate Apta-1

31 October 2019 - 10:47
Aptahem CEO Mikael Lindstam presents the company to investors and his focus is their lead candidate Apta-1 against sepsis....
Spotlight (Sweden)
Aptahem AB
Aptahem is active within biotechnology. The company conducts research and development of aptamer-based pharmaceuticals for the treatment of acute conditions caused by sepsis, blockage of blood vessels, stroke, and heart failure. Through early treatment, the pharmaceutical is intended to prevent damage to organs and tissue. A large part of the research is carried out in collaboration with partners...
Learn more about company

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date